@article{f9d10932fcdd4bc590b42e871a9ca2ae,
title = "Antidepressants might work for people with major depression: where do we go from here?",
author = "Andrea Cipriani and Georgia Salanti and Furukawa, \{Toshi A.\} and Matthias Egger and Stefan Leucht and Ruhe, \{Henricus G.\} and Turner, \{Erick H.\} and Atkinson, \{Lauren Z.\} and Anna Chaimani and Higgins, \{Julian P.T.\} and Yusuke Ogawa and Nozomi Takeshima and Yu Hayasaka and Hissei Imai and Kiyomi Shinohara and Aran Tajika and Ioannidis, \{John P.A.\} and Geddes, \{John R.\}",
note = "Funding Information: ACi is supported by the NIHR Oxford cognitive health Clinical Research Facility. JRG is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. TAF has received lecture fees from Eli Lilly, Janssen, Meiji, Mitsubishi-Tanabe, MSD, and Pfizer and consultancy fees from Takeda Science Foundation. He has received research support from Mochida and Mitsubishi-Tanabe. SL has received honoraria for consulting and advisory boards from Alkermes, Eli Lilly, Janssen, Johnson \& Johnson, Lundbeck, MedAvante, Roche, Otsuka, and Teva; lecture honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson \& Johnson, Lundbeck (Institute), Pfizer, Sanofi-Aventis, ICON, AbbVie, AOP Orphan, and Servier; for the preparation of educational material and publications from Lundbeck Institute and Roche; and Eli Lilly has provided medication for a trial with SL as the primary investigator. NT has received lecture fees from Otsuka and Meiji. YH has received lecture fees from Yoshitomi. All other authors declare no competing interests. ",
year = "2018",
month = jun,
doi = "10.1016/S2215-0366(18)30133-0",
language = "English",
volume = "5",
pages = "461--463",
journal = "The Lancet Psychiatry",
issn = "2215-0366",
publisher = "Elsevier Ltd.",
number = "6",
}
SDG 3 Good Health and Well-being